Form 4: InMed Pharma VP Disposes of Stock Options
Insider Transaction Report
InMed Pharmaceuticals Inc. Senior VP Eric C. Hsu reported the disposition of 70 employee stock options with an exercise price of $1,397.97.
Summary
- Eric C. Hsu, Senior VP, Pre-Clinical Research/Development at InMed Pharmaceuticals Inc. (INM), filed a Form 4.
- The filing reports the disposition of 70 employee stock options.
- These options had an exercise price of $1,397.97 per share, which was converted from a Canadian dollar exercise price of C$1,925.00 using an exchange rate of C$1.3770 = $US1.00.
- The options were exercisable as of December 16, 2020, and expired on December 15, 2025.
- Following this reported transaction, Eric C. Hsu beneficially owns 5,280 derivative securities directly.
Sentiment
Score: 3
Explanation: The expiration of employee stock options, especially with a high exercise price, often indicates that the stock price has not performed well enough to make exercising them profitable, which is a negative signal for the company's stock performance.
Negatives
- The disposition of 70 employee stock options on their expiration date suggests they likely expired unexercised, implying the stock price was below the high exercise price of $1,397.97.
Future Outlook
Not applicable for this type of filing.
Industry Context
This filing is a routine insider transaction report and does not provide broader industry context or trends.
Stakeholder Impact
- Shareholders may view the expiration of options as a negative signal regarding the company's stock performance, potentially impacting investor confidence.
Key Dates
| Date | Description |
|---|---|
| 12/16/2020 | Date employee stock option became exercisable |
| 12/15/2025 | Date of earliest transaction and expiration date of employee stock option |
| 12/16/2025 | Filing date of Form 4 |
Recommendation
sellThe expiration of 70 employee stock options with a high exercise price of $1,397.97 on their expiration date strongly suggests that the company's stock price was below this threshold, rendering the options worthless. This indicates significant underperformance of the stock, which is a negative signal for investors and warrants a 'sell' recommendation.
Keywords
InMed Pharmaceuticals, INM, Form 4, Insider Transaction, Stock Options, Beneficial Ownership, Eric C. Hsu, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.